Raschi E - Search Results

1

Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.

Antonazzo IC, Raschi E, Forcesi E, Riise T, Bjornevik K, Baldin E, De Ponti F, Poluzzi E. Antonazzo IC, et al. Among authors: raschi e. Expert Opin Drug Saf. 2018 Sep;17(9):869-874. doi: 10.1080/14740338.2018.1506763. Epub 2018 Aug 11. Expert Opin Drug Saf. 2018. PMID: 30058390

2

The hERG K+ channel: target and antitarget strategies in drug development.

Raschi E, Vasina V, Poluzzi E, De Ponti F. Raschi E, et al. Pharmacol Res. 2008 Mar;57(3):181-95. doi: 10.1016/j.phrs.2008.01.009. Epub 2008 Feb 2. Pharmacol Res. 2008. PMID: 18329284 Review.

3

Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Raschi E, et al. Br J Clin Pharmacol. 2009 Jan;67(1):88-98. doi: 10.1111/j.1365-2125.2008.03319.x. Epub 2008 Nov 17. Br J Clin Pharmacol. 2009. PMID: 19076158 Free PMC article. Review.

4

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

Poluzzi E, Raschi E, Moretti U, De Ponti F. Poluzzi E, et al. Among authors: raschi e. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):512-8. doi: 10.1002/pds.1746. Pharmacoepidemiol Drug Saf. 2009. PMID: 19358226

5

The beta3-adrenoceptor as a therapeutic target: current perspectives.

Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. Ursino MG, et al. Among authors: raschi e. Pharmacol Res. 2009 Apr;59(4):221-34. doi: 10.1016/j.phrs.2009.01.002. Epub 2009 Jan 24. Pharmacol Res. 2009. PMID: 19429463 Review.

6

hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.

Raschi E, Ceccarini L, De Ponti F, Recanatini M. Raschi E, et al. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1005-21. doi: 10.1517/17425250903055070. Expert Opin Drug Metab Toxicol. 2009. PMID: 19572824 Review.

7

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.

Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Raschi E, et al. Pharmacol Ther. 2010 Feb;125(2):196-218. doi: 10.1016/j.pharmthera.2009.10.002. Epub 2009 Oct 27. Pharmacol Ther. 2010. PMID: 19874849 Review.

8

Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Poluzzi E, et al. Among authors: raschi e. Drug Saf. 2010 Apr 1;33(4):303-14. doi: 10.2165/11531850-000000000-00000. Drug Saf. 2010. PMID: 20297862

9

Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.

Raschi E, Boriani G, De Ponti F. Raschi E, et al. Curr Drug Targets. 2011 Feb;12(2):263-86. doi: 10.2174/138945011794182728. Curr Drug Targets. 2011. PMID: 21126225

10

QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus.

Raschi E, Poluzzi E, Koci A, Boriani G, De Ponti F. Raschi E, et al. Br J Clin Pharmacol. 2011 Nov;72(5):839-41. doi: 10.1111/j.1365-2125.2011.04065.x. Br J Clin Pharmacol. 2011. PMID: 21777270 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

257 results

Search Page

Filters